Read about a candidate drug advancing into the federal Interventions Testing Program for lifespan evaluation and related public-private funding developments.
Key Takeaways
- LNS8801 is an oral selective GPER agonist with evidence of safety and target engagement
- LNS8801 was selected for the National Institute on Aging lifespan testing program in 2026
- ARPA-H awarded up to $22 million to advance LNS8801 for healthspan preservation